8.62
price up icon4.74%   0.39
after-market Handel nachbörslich: 8.62
loading
Schlusskurs vom Vortag:
$8.23
Offen:
$8.23
24-Stunden-Volumen:
870.98K
Relative Volume:
0.77
Marktkapitalisierung:
$494.31M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.6388
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+0.94%
1M Leistung:
-16.71%
6M Leistung:
+9.67%
1J Leistung:
-19.81%
1-Tages-Spanne:
Value
$8.14
$8.79
1-Wochen-Bereich:
Value
$7.91
$8.99
52-Wochen-Spanne:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
Firmenname
Regenxbio Inc
Name
Telefon
240-552-8181
Name
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
353
Name
Twitter
@REGENXBIO
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGNX
Regenxbio Inc
8.62 494.31M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Herabstufung Goldman Buy → Neutral
2025-02-07 Fortgesetzt Raymond James Outperform
2024-11-15 Fortgesetzt Morgan Stanley Overweight
2024-10-10 Fortgesetzt Raymond James Outperform
2024-06-07 Eingeleitet Goldman Buy
2024-03-11 Eingeleitet H.C. Wainwright Buy
2024-03-08 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-21 Fortgesetzt Raymond James Outperform
2023-11-01 Eingeleitet Stifel Buy
2023-06-02 Eingeleitet Robert W. Baird Outperform
2022-06-23 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Wedbush Neutral
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-01-06 Hochstufung Raymond James Outperform → Strong Buy
2020-12-16 Eingeleitet UBS Buy
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2019-08-20 Hochstufung SVB Leerink Underperform → Mkt Perform
2019-06-18 Bestätigt Chardan Capital Markets Buy
2019-06-14 Fortgesetzt Raymond James Outperform
2019-06-05 Bestätigt Chardan Capital Markets Buy
2019-02-25 Hochstufung Evercore ISI In-line → Outperform
2019-02-05 Hochstufung Raymond James Outperform → Strong Buy
2018-12-17 Bestätigt Chardan Capital Markets Buy
2018-11-08 Bestätigt BofA/Merrill Neutral
2018-08-08 Bestätigt Chardan Capital Markets Buy
2018-07-23 Herabstufung BofA/Merrill Buy → Neutral
2018-07-10 Bestätigt Chardan Capital Markets Buy
2018-05-09 Bestätigt Barclays Overweight
2018-04-09 Bestätigt Chardan Capital Markets Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-02-13 Eingeleitet Mizuho Neutral
2017-11-09 Fortgesetzt Morgan Stanley Overweight
Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025
pulisher
Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech

Jun 05, 2025
pulisher
Jun 05, 2025

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg

Jun 05, 2025
pulisher
Jun 05, 2025

Transcript : REGENXBIO Inc.Special Call - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Eagle-Tribune

Jun 02, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 30, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 28, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World

May 25, 2025
pulisher
May 23, 2025

Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com

May 23, 2025
pulisher
May 22, 2025

REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle

May 22, 2025
pulisher
May 21, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.

May 21, 2025

Finanzdaten der Regenxbio Inc-Aktie (RGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Regenxbio Inc-Aktie (RGNX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mills Kenneth T.
Director
May 12 '25
Sale
7.91
20,602
163,046
475,103
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):